• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Treatment outcomes for men with stage 2 non-seminoma undergoing primary RetroPeritoneal Lymph Node Dissection (RPLND): A systematic review

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Neuenschwander, A.
    Lonati, C.
    Papachristofilou, A.
    Cathomas, R.
    Rothermund, C.
    Templeton, A. J.
    Gulamhusein, Aziz
    Fischer, S.
    Gillessen, S.
    Hermanns, T.
    Mattei, A.
    Lorch, A.
    Fankhauser, C. D.
    Show allShow less
    Affiliation
    Kantonsspital St.Gallen, Dept. of Urology, St.Gallen, Switzerland
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Introduction & Objectives: Current guidelines recommend primary RPLND as a treatment option for tumour marker negative stage 2 non seminoma. RPLND offers several potential advantages compared to cisplatin-based first-line chemotherapy, including: 1) clarification of ambiguous cN+ on imaging; 2) resection of potentially chemo-resistant histologies, which reduces the risk of late recurrence and the need for post chemotherapy RPLND; and 3) limited long-term morbidity. The aim of this review is to examine the oncological outcomes of RPLND for men with clinical stage 2 disease with or without elevated tumour markers. Materials & Methods: A systematic review was conducted to summarize treatment options and outcomes in the published literature, using the electronic databases MEDLINE, EMBASE and Cochrane Database of Systematic Reviews. Results: Of 4,386 total records, 448 full texts were screened and 13 studies were selected for the review, of which 12 were retrospective in nature. The studies included in the review contributed data from 892 men. Studies used different inclusion criteria (e.g., amount of teratoma in orchiectomy specimen, level of preoperative tumour markers, nodal size, synchronous or metachronous disease). Among men with enlarged retroperitoneal lymph nodes (cN+), 13–53% had false positive findings in imaging; in other words, no cancer was found in the RPLND specimen (pN0). Six of the studies used a bilateral or modified template. A bilateral or modified unilateral template was used in one study each. No template description was available for the remaining five studies. Nerve sparing was mentioned in three studies. In the case of pN+ disease, additive systemic treatment was given to most men in five studies, whereas in six studies, additive chemotherapy was only used for participants who had large or several affected lymph nodes or had persistently elevated tumour markers. One study did not mention the indication for chemotherapy, and in the last study, no additive chemotherapy was prescribed. Recurrence after RPLND without additive systemic chemotherapy was observed in 19–37% of participants, and recurrence after RPLND with additive systemic chemotherapy was observed in 0–7% of participants. Overall, survival rates ranged from 88–100% of participants, and disease-specific survival rates ranged from 97–100% of participants. Conclusions: The literature describing surgery among men with enlarged retroperitoneal lymph nodes on cross-sectional imaging is heterogenous in selection criteria, surgical templates, additive therapy, and length of follow-up, which prevents a meta-analysis at the study level.
    Citation
    Neuenschwander A, Lonati C, Papachristofilou A, Cathomas R, Rothermund C, Templeton AJ, et al. Treatment outcomes for men with stage 2 non-seminoma undergoing primary RetroPeritoneal Lymph Node Dissection (RPLND): A systematic review. European Urology. 2022 Feb;81:S840-S. PubMed PMID: WOS:000812320400553.
    Journal
    European Urology
    URI
    http://hdl.handle.net/10541/625498
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.